ATE382370T1 - Antikörper-serumprotein hybride - Google Patents

Antikörper-serumprotein hybride

Info

Publication number
ATE382370T1
ATE382370T1 AT99954209T AT99954209T ATE382370T1 AT E382370 T1 ATE382370 T1 AT E382370T1 AT 99954209 T AT99954209 T AT 99954209T AT 99954209 T AT99954209 T AT 99954209T AT E382370 T1 ATE382370 T1 AT E382370T1
Authority
AT
Austria
Prior art keywords
antibodies
serum protein
protein hybrid
hybrid
proteins
Prior art date
Application number
AT99954209T
Other languages
English (en)
Inventor
Bryan John Smith
Original Assignee
Celltech Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Therapeutics Ltd filed Critical Celltech Therapeutics Ltd
Application granted granted Critical
Publication of ATE382370T1 publication Critical patent/ATE382370T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99954209T 1998-11-10 1999-11-10 Antikörper-serumprotein hybride ATE382370T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824632.5A GB9824632D0 (en) 1998-11-10 1998-11-10 Biological compounds

Publications (1)

Publication Number Publication Date
ATE382370T1 true ATE382370T1 (de) 2008-01-15

Family

ID=10842195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99954209T ATE382370T1 (de) 1998-11-10 1999-11-10 Antikörper-serumprotein hybride

Country Status (8)

Country Link
US (2) US7105160B1 (de)
EP (2) EP1128847B1 (de)
AT (1) ATE382370T1 (de)
AU (1) AU1062700A (de)
DE (1) DE69937899T2 (de)
ES (1) ES2299268T3 (de)
GB (1) GB9824632D0 (de)
WO (1) WO2000027435A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
US20040220086A1 (en) * 2001-10-17 2004-11-04 Faulk W. Page Methods and materials for targeting and affecting selected cells
EP1900753B1 (de) 2002-11-08 2017-08-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
WO2010010119A1 (en) 2008-07-22 2010-01-28 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
PT2438087T (pt) 2009-06-05 2017-08-04 Ablynx Nv Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
EP3309176B1 (de) 2009-12-14 2025-10-01 Ablynx N.V. Variable einzeldomänen-antikörper gegen ox40l, konstrukte und ihre therapeutische verwendung
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (de) 2010-05-06 2017-12-20 Novartis AG Zusammensetzungen und verfahren zur verwendung von therapeutischen antikörpern gegen ldl-assoziiertes protein 6 (lrp6)
EP2571901B1 (de) 2010-05-20 2019-01-02 Ablynx N.V. Biologische stoffe im zusammenhang mit her3
AU2011328246B2 (en) 2010-11-08 2016-06-30 Ablynx N.V. CXCR2 binding polypeptides
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2723772A1 (de) 2011-06-23 2014-04-30 Ablynx N.V. Gegen ige gerichtete variable immunglobulin-einzeldomänen
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
BR112019010061A2 (pt) 2016-11-16 2019-08-13 Ablynx Nv polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
NZ759601A (en) 2017-06-02 2023-06-30 Merck Patent Gmbh Aggrecan binding immunoglobulins
CN117050184A (zh) 2017-12-28 2023-11-14 南京传奇生物科技有限公司 针对tigit的单域抗体和其变体
CN111699200B (zh) 2018-01-15 2023-05-26 南京传奇生物科技有限公司 针对pd-1的单域抗体和其变体
TW202003567A (zh) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 針對lag-3之單一結構域抗體及其用途
CN117321076A (zh) 2021-02-19 2023-12-29 美国卫生及公众服务部代表 中和SARS-CoV-2的单结构域抗体
EP4605077A1 (de) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Gegen den melanocortin-4-rezeptor gerichtete aminosäuresequenzen und polypeptide damit zur behandlung von mc4r-bedingten erkrankungen und störungen
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
TW202540169A (zh) 2023-11-08 2025-10-16 法商賽諾菲公司 基於ｃｄ２５的溶酶體降解物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749570A (en) * 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
KR930701201A (ko) * 1990-07-03 1993-06-11 에프.지.엠.헤르만스.에이.지.제이.베르미렌 면역반응성 화합물
CA2074945A1 (en) * 1990-11-30 1992-05-31 Atsushi Isoai Tumor cell invasion-inhibiting peptides, peptide complexes and cancer metastasis inhibitors
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0602290B1 (de) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antikörper-konjugiertes-Hepatitis B-Oberflächenantigen und dessen Verwendung
JPH09509428A (ja) * 1994-02-23 1997-09-22 カイロン コーポレイション 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物
WO1995033492A1 (en) * 1994-06-09 1995-12-14 Houston Biotechnology Incorporated Methods and compositions for modulation of wound healing
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
JP4046354B2 (ja) * 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
WO1998048838A1 (en) * 1997-04-29 1998-11-05 Nycomed Imaging As Compounds

Also Published As

Publication number Publication date
EP1808155A3 (de) 2007-10-31
EP1128847B1 (de) 2008-01-02
GB9824632D0 (en) 1999-01-06
EP1128847A1 (de) 2001-09-05
AU1062700A (en) 2000-05-29
US20060263375A1 (en) 2006-11-23
EP1808155A2 (de) 2007-07-18
DE69937899D1 (de) 2008-02-14
US7105160B1 (en) 2006-09-12
ES2299268T3 (es) 2008-05-16
DE69937899T2 (de) 2008-12-24
WO2000027435A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
ATE382370T1 (de) Antikörper-serumprotein hybride
ATE58297T1 (de) Kupplungsmittel zum radiomarkieren von proteinen.
AU6264686A (en) Antibody complexes of hapten-modified diagnostic or therapeutic agents
AU563356B2 (en) Conjugate of enzyme and antibody
DE69434725D1 (de) Zell- und Serumproteinanker und Konjugate
EP1378525A3 (de) Humanisierte Antikörper die and das gleiche Antigen wie Antikörper NR-LU-13 binden und deren Verwendung in "Pretargeting" Verfahren
DE69033705D1 (de) Hybride immunglobuline
DE69020007D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
ATE132197T1 (de) Monoklonale antikörper
DE69434384D1 (de) Metalkomplexbildner
FI970979A0 (fi) Muokatut ihmisen C3-proteiinit
GB2278357B (en) Humanised antibodies directed against A33 antigen
DE69020182D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
ATE131069T1 (de) Composition comprising at least two different antibodies or fragments thereof.
ATE122723T1 (de) Retinoblastoma-genprodukt-antikörper und deren verwendungen.
FI971879L (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
AU5569600A (en) Novel protein and dna thereof
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties